Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 44370 TA for acute migraine attack
2008-000079-31Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of BI 44370 in migraine (5 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Pain-free response at 2 hours. Started Jun 2008; status: completed.
02
Drugs
BI 44370
03
Conditions
migraine
Beyond the preview
Go deeper on 2008-000079-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000079-31.